In re: Diet Drugs by unknown
2020 Decisions 
Opinions of the United 
States Court of Appeals 
for the Third Circuit 
1-21-2020 
In re: Diet Drugs 
Follow this and additional works at: https://digitalcommons.law.villanova.edu/thirdcircuit_2020 
Recommended Citation 
"In re: Diet Drugs" (2020). 2020 Decisions. 57. 
https://digitalcommons.law.villanova.edu/thirdcircuit_2020/57 
This January is brought to you for free and open access by the Opinions of the United States Court of Appeals for 
the Third Circuit at Villanova University Charles Widger School of Law Digital Repository. It has been accepted for 




UNITED STATES COURT OF APPEALS 






IN RE: DIET DRUGS (PHENTERMINE/FENFLURAMINE/DEXFENFLURAMINE) 
 PRODUCTS LIABILITY LITIGATION  
 
 
      NORMA SCHLAGER, 
            Appellant 
   _______________________________________ 
 
On Appeal from the United States District Court 
for the Eastern District of Pennsylvania 
(No. 2-99-cv-20593; 2-11-md-01203; 2-15-md-01203) 
District Judge: Honorable Harvey Bartle, III 
   _______________________________________    
 
Submitted Pursuant to Third Circuit L.A.R. 34.1(a) 
January 16, 2020 
 
Before:  HARDIMAN, PORTER, and PHIPPS, Circuit Judges. 
 





                                              
*  This disposition is not an opinion of the full Court and pursuant to I.O.P. 5.7 does not 
constitute binding precedent.   
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PHIPPS, Circuit Judge.   
This appeal addresses the timeliness of a claim for benefits under a nationwide 
class action settlement related to the ingestion of diet drugs and the onset of valvular 
heart disease.  The terms of the settlement agreement provided for two damage matrices: 
a low-level matrix and a high-level matrix.  Norma Schlager is a class member who 
initially sought low-level matrix benefits.  She now seeks high-level matrix benefits due 
to valvular heart surgery she underwent on September 2, 2010, and a stroke she had on 
June 29, 2014. 
Due to the terms of the settlement agreement and her lack of an opt-out, 
Schlager’s ability to recover high-level matrix benefits is governed by the Seventh 
Amendment to the settlement agreement.  Under that provision, to seek high-level matrix 
benefits after initially requesting low-level matrix benefits, a class member must meet 
certain requirements.  For Schlager, who last ingested diet drugs in 1995, she needed to 
experience a qualifying event triggering a claim for benefits (a) no later than 
December 31, 2011, and (b) while she was 79 years old or under.  And to request high-
level matrix benefits, she needed to submit a document, referred to as the Green Form, to 
the administrator of the settlement trust.  The Green Form had to be completed either by 
her or her representative, and a physician. 
Originally, the Seventh Amendment did not include a time period for submitting a 
Green Form.  But an order entered by the District Court, referred to as ‘Court Approved 
Procedure 16,’ imposed deadlines for the Green Form.  That order dictated that a 
completed Green Form must have been received within four years after the later of (i) the 
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date of the order, which was entered on November 8, 2010, or (ii) the first diagnosis of 
“the last occurring condition or event upon which the claim for [high-level matrix 
benefits] is based.”  Court Approved Procedure No. 16 at 2, In re Diet Drugs 
(Phentermine/Fenfluramine/Dexfenfluramine) Products Liab. Litig., 2:11-md-01203 
(E.D. Pa. Nov. 5, 2001). 
Here, Schlager seeks Level IV high-level matrix benefits based on her 2010 
surgery and her 2014 stroke.  To obtain those benefits, Schlager completed and submitted 
a Green Form, which was received on February 6, 2017.  The settlement trust 
administrator denied Schlager benefits, and Schlager contested that outcome. 
Consistent with the terms of the class action settlement agreement, the District 
Court then referred the dispute to arbitration.  The arbitrator upheld the denial of benefits 
related to Schlager’s 2010 surgery because the Green Form was submitted too late.  Her 
2017 Green Form was received over four years past both the entry of Court Approved 
Procedure 16 and her 2010 surgery.  The arbitrator also upheld the denial of benefits 
related to Schlager’s 2014 stroke for two reasons: her stroke occurred after December 31, 
2011, and she was 81 years old at the time. 
Schlager then appealed the arbitrator’s decision to the District Court, which, in 
exercising jurisdiction, see 28 U.S.C. § 1332, affirmed the arbitrator’s award. 
Schlager appealed again to this Court.  With jurisdiction over a final order 
affirming an arbitration award, see 28 U.S.C. § 1291, we review factual findings for clear 
error and legal conclusions de novo.  See Sutter v. Oxford Health Plans LLC, 675 F.3d 




This appeal is not the first time that this Court has addressed an untimely claim by 
Schlager to recover for her 2010 surgery.  In 2015, she submitted two Green Forms 
requesting Level III high-level matrix benefits based on that surgery.  See generally In re 
Diet Drugs (Phentermine/Fenfluramine/Dexfenfluramine) Products Liab. Litig., 
763 F. App’x 237 (3d Cir. 2019).  This Court determined that those Green Forms were 
late and that their untimeliness could not be excused based on due process, lack of notice, 
equitable tolling, or other reasons.  Id. at 241-43, 243 n.25.   
This time, Schlager seeks to recover based on a more untimely Green Form, which 
sought greater benefits – those under Level IV, up from Level III.  Schlager argues that 
the 2017 Green Form should be deemed timely due to the discovery rule, the relation-
back doctrine, equitable tolling, class action protocols, and guidance from the Federal 
Judicial Center.  To put it mildly, none of those arguments have any merit.   
Schlager first attempts to invoke discovery rule, by asserting that the deadlines 
imposed by Court Approved Procedure 16 “worked a fraud on [her].”  That argument 
misapprehends the discovery rule at a fundamental level.  The discovery rule tolls a 
statute of limitations in certain instances based on the new discovery of an injury and its 
cause – not for the discovery of a court-approved procedure for submitting claims.  See 
Schmidt v. Skolas, 770 F.3d 241, 251 (3d Cir. 2014); Crouse v. Cyclops Indus., 745 A.2d 
606, 611 (Pa. 2000); see also Rotkiske v. Klemm, 140 S. Ct. 355, 361 (2019).   
Schlager next argues that the relation-back doctrine should be applied to her 2017 
Green Form.  Specifically, she argues that the 2017 Green Form should relate back to her 
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2015 Green Forms.  The relation-back doctrine is a rule of pleading, see Krupski v. Costa 
Crociere S. p. A., 560 U.S. 538, 547 (2010), and it does not apply to claim forms 
submitted to a settlement trust.  Nor would relation-back preserve Schlager’s claims.  As 
this Court previously held, even those 2015 Green Forms were untimely.  See In re Diet 
Drugs, 763 F. App’x at 243. 
Schlager’s equitable tolling arguments also come up empty.  None of the 
circumstances necessary for equitable tolling are present here.  See In re Cmty. Bank of N. 
Va. Mortg. Lending Practices Litig., 795 F.3d 380, 400 (3d Cir. 2015) (setting forth three 
circumstances in which equitable tolling has been permitted).  Nothing indicates that 
Schlager was actively misled, that she was prevented from filing a Green Form, or that 
she filed a Green Form in the wrong forum.  See id. 
In next arguing that she acted with “extraordinary diligence” in pursuing a claim 
for her 2010 surgery, Schlager re-packages an argument previously rejected by this 
Court.  See In re Diet Drugs, 763 F. App’x at 242-43.  Nothing she presents this time 
around favors a different outcome. 
In another effort to justify her untimeliness, Schlager attempts to blame the 
settlement trust administrator.  Specifically, she contends that rather than permitting her 
to continue pro se, the trust administrator should have notified her that she was entitled to 
the service of class counsel.  That obligation of the trust administrator to notify a pro se 
claimant of the availability of legal services by class counsel arises from a court order, 
referred to as ‘Court Approved Procedure 3.’  That duty, however, is limited to instances 
in which “a pro se claimant is likely to be unable to complete a claim without assistance, 
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would benefit from assistance of counsel and is likely to be prejudiced as a result of 
absence of assistance of counsel.”  Court Approved Procedure No. 3 at 2, In re Diet 
Drugs (Phentermine/Fenfluramine/Dexfenfluramine) Products Liab. Litig., 
2:11-md-01203 (E.D. Pa. Nov. 15, 2001).  And based on Schlager’s prior pro se 
submission of a Green Form in 2003 – allowing her to obtain low-level matrix benefits – 
the conditions prompting notice by the trust administrator were not present with respect 
to Schlager’s subsequent Green Form submissions. 
Schlager closes with the claim that the District Court erred by failing to follow 
model notice procedures published by the Federal Judicial Center.  Perhaps suggestive of 
a lack of any potential merit, Schlager does not adequately develop that argument, which 
does not provide a basis for overturning the judgment against her.  See generally Sw. Pa. 
Growth All. v. Browner, 121 F.3d 106, 122 (3d Cir. 1997) (“[A]ppellate courts generally 
should not address legal issues that the parties have not developed through proper 
briefing.”). 
II 
 Regardless of the timeliness of her Green Form, Schlager cannot recover for her 
2014 stroke under the terms of the settlement agreement.  The stroke occurred on 
June 29, 2014, after the December 31, 2011 deadline for a qualifying event.  Also, 
because Schlager was 81 years old when she suffered that stroke, she was not eligible to 
recover benefits for it. 
III 
For the foregoing reasons, we will affirm the judgment of the District Court. 
